- Supported exchanges /
- F /
- 74C.F
CROSSJECT SA EO -10 (74C F) stock market data APIs
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France.
CROSSJECT SA EO -10 Financial Data Overview
2.35 | |
2.35 | |
- | |
2.35 | |
2.35 | |
1.43-5.76 | |
104 M | |
41 151 K | |
2 497 K | |
1.005 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
CROSSJECT SA EO -10 Fundamental Data is available in our Financial Data APIs
- Net Revenue 2 497 K
- EBITDA -13 044 500
- Earnings Per Share -0.23
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get CROSSJECT SA EO -10 Earnings via APIs
- Latest Release 2024-09-23
- EPS/Forecast NaN
Get CROSSJECT SA EO -10 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: